{
  "id": 8097320,
  "title": "Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN",
  "url": "https://urgent.news/2026/09/17/phase-3-pediatric-empaveli-data-published-in-clinical-journal-of-the",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-17T20:19:44.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/phase-3-pediatric-empaveli-data-published-in-clinical-journal-of-the-american-society-of-nephrology-show-reduction-in-proteinuria-and-stabilized-kidney-function-in-adolescents-with-c3g-or-primary-ic-m"
  },
  "original_language": "en",
  "account": null,
  "summary": "EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based on VALIANT study Publication follows a recent FDA label update to expand EMPAVELI’s indication to include reducing the loss of kidney function in patients 12 years and […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}